Clopidogrel

Generic Name: Clopidogrel

Brand Names: Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₆ClNO_₂S

CAS Number: 113665-84-2

Unique Ingredient Identifier: A74586SNO7

Background: Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication: 1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；

2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；

3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events

Clinical Trials

Evaluation of Platelet Aggregability in Patients with Non-small Cell Lung Carcinomas

Phase 2

Active, not recruiting

Conditions: Assessment of Platelet Aggregability in Patients Patients with Non-small Cell Lung Carcinoma

Interventions: Drug: Clopidogrel

First Posted Date: 2025-03-12

Last Posted Date: 2025-03-12

Lead Sponsor: University of Sao Paulo

Target Recruit Count: 100

Registration Number: NCT06872541

Locations: 🇧🇷
Heart Institute (InCor) / University of São Paulo, São Paulo, Brazil

Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study

Phase 4

Recruiting

Conditions: Coronary Artery Disease

Interventions: Drug: clopidogrel 75 mg
Drug: Prasugrel 5 mg

First Posted Date: 2025-02-11

Last Posted Date: 2025-04-15

Lead Sponsor: University of Florida

Target Recruit Count: 78

Registration Number: NCT06821191

Locations: 🇺🇸
University of Florida, Jacksonville, Florida, United States

Evaluation of Platelet Aggregability in Patients with Takayasu's Arteritis

Active, not recruiting

Conditions: Takayasu Arteritis (TAK)
Vasculitis, Systemic

Interventions: Drug: Clopidogrel

First Posted Date: 2025-02-04

Last Posted Date: 2025-02-04

Lead Sponsor: Jose Carlos Nicolau

Target Recruit Count: 100

Registration Number: NCT06807788

Locations: 🇧🇷
Heart Institute (InCor) / University of São Paulo, São Paulo, São paulo, Brazil

Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR

Phase 4

Not yet recruiting

Conditions: Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
High Bleeding Risk

Interventions: Drug: P2Y12 antagonist monotherapy
Drug: clopidogrel + aspirin

First Posted Date: 2025-01-08

Last Posted Date: 2025-05-18

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 3000

Registration Number: NCT06763744

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis

Phase 4

Not yet recruiting

Conditions: Cerebral Infarction
Stenosis Artery

Interventions: Drug: Aspirin
Drug: Clopidogrel
Drug: Cilostazol
Drug: Placebo

First Posted Date: 2025-01-03

Last Posted Date: 2025-01-06

Lead Sponsor: Asan Medical Center

Target Recruit Count: 2340

Registration Number: NCT06757764

Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases

Recruiting

Conditions: Stroke, Ischemic
Small Vessel Cerebrovascular Disease
White Matter Hyperintensity

Interventions: Drug: Clopidogrel
Drug: Aspirin
Drug: Cilostazol + Isosorbide Mononitrate

First Posted Date: 2024-12-04

Last Posted Date: 2025-03-28

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 300

Registration Number: NCT06715007

Locations: 🇨🇳
the First affiliated hospital of Nanjing Medical University, Nanjing, Jiangsu, China

Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy in Symptomatic ICAD

Not Applicable

Not yet recruiting

Conditions: Intracranial Atherosclerosis

Interventions: Genetic: Point-of-Care CYP2C19 Testing
Drug: ticagrelor + aspirin
Drug: clopidogrel + aspirin

First Posted Date: 2024-12-03

Last Posted Date: 2025-05-18

Lead Sponsor: Sunnybrook Health Sciences Centre

Target Recruit Count: 100

Registration Number: NCT06714526

Locations: 🇨🇦
University of Calgary, Calgary, Alberta, Canada
🇨🇦
Dr. Mark I. Boulos - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel

Early Phase 1

Recruiting

Conditions: Interaction

Interventions: Drug: Cannabidiol in the form of hemp
Drug: Clopidogrel

First Posted Date: 2024-11-18

Last Posted Date: 2024-11-18

Lead Sponsor: Washington State University

Target Recruit Count: 24

Registration Number: NCT06692933

Locations: 🇺🇸
Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, Washington, United States

Clopidogrel Vs. Aspirin in Patients with S. Aureus Bacteremia

Phase 4

Not yet recruiting

Conditions: Staphylococcus Aureus Endocarditis
Staphylococcus Aureus Septicemia
Staphylococcus Aureus Bloodstream Infection

Interventions: Drug: Clopidogrel
Drug: Aspirin

First Posted Date: 2024-10-21

Last Posted Date: 2024-10-21

Lead Sponsor: Todd C. Lee MD MPH FIDSA

Target Recruit Count: 300

Registration Number: NCT06650488

Locations: 🇨🇦
McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital), Montreal, Quebec, Canada

Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).

Phase 2

Recruiting

Conditions: Ischemic Stroke

Interventions: Drug: Tiprogrel
Drug: Clopidogrel

First Posted Date: 2024-09-19

Last Posted Date: 2025-03-07

Lead Sponsor: Tianjin Institute of Pharmaceutical Research Co., Ltd

Target Recruit Count: 600

Registration Number: NCT06601127

Locations: 🇨🇳
Central Hospital Affiliated to Shenyang Medical College, Shenyang, Liaoning, China
🇨🇳
Beijing Tiantan Hosptial, Capital Medical University, Beijing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy